Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-associated deaths worldwide. Treatment with immune checkpoint antibodies has shown promise in advanced HCC, but the response is only 15–20%. We discovered a potential target for the treatment of HCC, the cholecystokinin-B receptor (...

Descripción completa

Detalles Bibliográficos
Autores principales: Shivapurkar, Narayan, Gay, Martha D., He, Aiwu (Ruth), Chen, Wenqiang, Golnazar, Shermineh, Cao, Hong, Duka, Tetyana, Kallakury, Bhaskar, Vasudevan, Sona, Smith, Jill P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965856/
https://www.ncbi.nlm.nih.gov/pubmed/36835036
http://dx.doi.org/10.3390/ijms24043625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965856/
https://www.ncbi.nlm.nih.gov/pubmed/36835036
http://dx.doi.org/10.3390/ijms24043625

Ejemplares similares